Effect of TYB-2285 on antigen-induced airway responses in sheep

被引:7
作者
Abraham, WM [1 ]
Ahmed, A [1 ]
Cortes, A [1 ]
Sielczak, M [1 ]
Wantanabe, A [1 ]
机构
[1] TOYOBO CO LTD,PHARMACEUT RES CTR,DEPT PHARMACOL,OTSU,SHIGA,JAPAN
来源
PULMONARY PHARMACOLOGY | 1996年 / 9卷 / 01期
关键词
asthma; bronchoconstriction; airway hyperresponsiveness; animal model;
D O I
10.1006/pulp.1996.0006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We studied the effect of a new antiallergic compound, TYB-2285 (3,5-bis(acetoxyacetylamino)-4-chlorobenzonitrile), on antigen-induced early and late bronchoconstriction and airway responsiveness in conscious allergic sheep. The same general protocol was used for all studies, except that the dosage and time of TYB-2285 treatment was varied. The basic protocol consisted of determining airway responsiveness to inhaled carbachol, then measuring the airway responses to Ascaris suum antigen challenge followed 1 day later by a post challenge assessment of airway responsiveness. Specific lung resistance (SR(L)) was used to measure the airway responses to antigen and carbachol and the concentration of carbachol that caused a 400% increase in SR(L) (PC400) was used as a measure of airway responsiveness. All protocols were of crossover design, such that each sheep served as its own control and each protocol employed six to eight animals. In all instances, TYB-2285 or vehicle control (methylcellulose) was given orally. When TYB-2285 (100 mg/kg) was given at 16 and 2 h before the challenge, the early response, the late response and the post antigen-induced airway hyperresponsiveness (AHR) as indicated by a decrease in the PC400 was inhibited significantly. TYB-2285 (100 mg/kg), when given 1 h after challenge, inhibited the late response and AHR significantly. TYB-2285 (100 mg/kg), when given 8 h after the challenge, also inhibited the antigen-induced AHR. When animals were given TYB-2285 (100 mg/kg) at 32, 56 and 80 h after the challenge, the antigen-induced AHR that persisted (for 1 week) in the control trial was reversed to the normal level. TYB-2285 (30 mg/kg), when given at 1, 32, 56 and 80 h after the challenge, inhibited late response slightly and reversed the persistent AHR to the normal level. At lower doses (3 and 10 mg/kg) there was no protection of the early response, the late response or AHR. Pretreatment with TYB-2285 (100 mg/kg) also prevented the antigen-induced influx of eosinophils in bronchoalveolar lavage obtained 24 h after segmental antigen challenge. TYB-2285 did not inhibit histamine or LTD(4)-induced bronchoconstriction nor did the active metabolites of TYB-2285, TC-286 and TC-326 inhibit acetylcholine-induced contraction of sheep tracheal smooth muscle. These results suggest that TYB-2285 has both antiallergic and antiinflammatory properties in the sheep model of allergic bronchoconstriction. The compound demonstrates both prophylactic and therapeutic activity and, therefore, may be potentially useful in the treatment of allergen-induced airway disease. (C) 1996 Academic Press Limited.
引用
收藏
页码:49 / 58
页数:10
相关论文
共 32 条
[21]   FIBRONECTIN RECEPTOR INTEGRINS ARE INVOLVED IN MAST-CELL ACTIVATION [J].
RA, CS ;
YASUDA, M ;
YAGITA, H ;
OKUMURA, K .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 94 (03) :625-628
[22]   THE ROLE OF THE LEUKOCYTE ADHESION MOLECULES VLA-4, LFA-1, AND MAC-1 IN ALLERGIC AIRWAY RESPONSES IN THE RAT [J].
RABB, HA ;
OLIVENSTEIN, R ;
ISSEKUTZ, TB ;
RENZI, PM ;
MARTIN, JG .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 149 (05) :1186-1191
[23]   SEPARATION OF LATE BRONCHIAL RESPONSES FROM AIRWAY HYPERRESPONSIVENESS IN ALLERGIC SHEEP [J].
SOLER, M ;
SIELCZAK, M ;
ABRAHAM, WM .
JOURNAL OF APPLIED PHYSIOLOGY, 1991, 70 (02) :617-623
[24]  
STEBENS WHM, 1995, AM J RESP CRIT CARE, V151, P1526
[25]   INCREASED LEUKOTRIENE-E4 EXCRETION DURING ANTIGEN-INDUCED BRONCHOCONSTRICTION IN ALLERGIC SHEEP [J].
TAGARI, P ;
ABRAHAM, WM ;
MCGOLRICK, J ;
CHARLESON, S ;
SOLER, M ;
AHMED, A ;
CORTEZ, A ;
FORDHUTCHINSON, AW .
JOURNAL OF APPLIED PHYSIOLOGY, 1990, 68 (04) :1321-1327
[26]   EFFECT OF TYB-2285 ON HISTAMINE-RELEASE FROM HUMAN BASOPHILS IN THE PRESENCE ABSENCE OF IL-3 [J].
TOMINAGA, T ;
WATANABE, A ;
HAYASHI, H ;
YANAGIHARA, Y ;
KODA, A .
GENERAL PHARMACOLOGY, 1993, 24 (02) :345-348
[27]  
TOMINAGA T, 1996, IN PRESS ALLERGOLOGY
[28]  
TOMINAGA T, 1996, GEN PHARM
[29]   CHARACTERIZATION OF SULFIDOPEPTIDE LEUKOTRIENE RESPONSES IN SHEEP TRACHEAL SMOOTH-MUSCLE INVITRO [J].
TOMIOKA, K ;
JACKOWSKI, JT ;
ABRAHAM, WM .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1991, 69 (06) :805-811
[30]   ASTHMA SYMPTOMS AND AIRWAY HYPERRESPONSIVENESS ARE LOWER DURING TREATMENT WITH NEDOCROMIL SODIUM THAN DURING TREATMENT WITH REGULAR INHALED ALBUTEROL [J].
WASSERMAN, SI ;
FURUKAWA, CT ;
HENOCHOWICZ, SI ;
MARCOUX, JP ;
PRENNER, BM ;
FINDLAY, SR ;
GROSS, GN ;
HUDSON, LD ;
MYERS, DJ ;
STEINBERG, P .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1995, 95 (02) :541-547